166 related articles for article (PubMed ID: 33420417)
21. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
[TBL] [Abstract][Full Text] [Related]
22. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Pflueger D; Rickman DS; Sboner A; Perner S; LaFargue CJ; Svensson MA; Moss BJ; Kitabayashi N; Pan Y; de la Taille A; Kuefer R; Tewari AK; Demichelis F; Chee MS; Gerstein MB; Rubin MA
Neoplasia; 2009 Aug; 11(8):804-11. PubMed ID: 19649210
[TBL] [Abstract][Full Text] [Related]
23. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
Tomlins SA; Aubin SM; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A; Penabella Y; Day JR; Varambally R; Han B; Wood D; Wang L; Sanda MG; Rubin MA; Rhodes DR; Hollenbeck B; Sakamoto K; Silberstein JL; Fradet Y; Amberson JB; Meyers S; Palanisamy N; Rittenhouse H; Wei JT; Groskopf J; Chinnaiyan AM
Sci Transl Med; 2011 Aug; 3(94):94ra72. PubMed ID: 21813756
[TBL] [Abstract][Full Text] [Related]
24. Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
Necchi A; Cucchiara V; Grivas P; Bratslavsky G; Jacob J; Spiess PE; Sokol ES; Killian JK; Lin D; Ramkissoon S; Huang RSP; Madison RW; Venstrom JM; Schrock AB; Danziger N; Decker B; Gjoerup O; Graf RP; Oxnard GR; Tukachinsky H; Ross JS
Cancer; 2021 Dec; 127(24):4557-4564. PubMed ID: 34379803
[TBL] [Abstract][Full Text] [Related]
25. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
26. Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.
Heselmeyer-Haddad KM; Berroa Garcia LY; Bradley A; Hernandez L; Hu Y; Habermann JK; Dumke C; Thorns C; Perner S; Pestova E; Burke C; Chowdhury SA; Schwartz R; Schäffer AA; Paris PL; Ried T
Am J Pathol; 2014 Oct; 184(10):2671-86. PubMed ID: 25131421
[TBL] [Abstract][Full Text] [Related]
27. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
29. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
[TBL] [Abstract][Full Text] [Related]
30. Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.
Pakula H; Linn DE; Schmidt DR; Van Gorsel M; Vander Heiden MG; Li Z
Methods Mol Biol; 2018; 1786():131-151. PubMed ID: 29786791
[TBL] [Abstract][Full Text] [Related]
31. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
[TBL] [Abstract][Full Text] [Related]
32. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
33. NCOR1 may be a potential biomarker of a novel molecular subtype of prostate cancer.
Tang L; Zhang L; Liu L; Dong L; Dong Y; Zhu W; Wang H
FEBS Open Bio; 2020 Dec; 10(12):2678-2686. PubMed ID: 33058520
[TBL] [Abstract][Full Text] [Related]
34. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
35. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.
Brase JC; Johannes M; Mannsperger H; Fälth M; Metzger J; Kacprzyk LA; Andrasiuk T; Gade S; Meister M; Sirma H; Sauter G; Simon R; Schlomm T; Beissbarth T; Korf U; Kuner R; Sültmann H
BMC Cancer; 2011 Dec; 11():507. PubMed ID: 22142399
[TBL] [Abstract][Full Text] [Related]
36. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
37. ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance.
Vicentini C; Cantù C; Antonello D; Simbolo M; Mafficini A; Luchini C; Rusev B; Porcaro AB; Iacovelli R; Fassan M; Corbo V; Brunelli M; Artibani W; Scarpa A; Lawlor RT
Pathol Res Pract; 2018 Oct; 214(10):1675-1680. PubMed ID: 30190183
[TBL] [Abstract][Full Text] [Related]
38. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.
Attard G; Clark J; Ambroisine L; Fisher G; Kovacs G; Flohr P; Berney D; Foster CS; Fletcher A; Gerald WL; Moller H; Reuter V; De Bono JS; Scardino P; Cuzick J; Cooper CS;
Oncogene; 2008 Jan; 27(3):253-63. PubMed ID: 17637754
[TBL] [Abstract][Full Text] [Related]
39. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
40. Molecular Composition of Genomic
Krumbholz M; Agaimy A; Stoehr R; Burger M; Wach S; Taubert H; Wullich B; Hartmann A; Metzler M
Dis Markers; 2019; 2019():5085373. PubMed ID: 31915468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]